QUIDELORTHO CORP Restructuring and Related Cost, Incurred Cost
QUIDELORTHO CORP (QDEL) reported Restructuring and Related Cost, Incurred Cost of $28.10 million for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2026-08-07
- QUIDELORTHO CORP restructuring and related cost, incurred cost for the quarter ending 2026-06-28 was $7.70M.
- QUIDELORTHO CORP restructuring and related cost, incurred cost for the quarter ending 2026-03-29 was $20.40M.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month |
|---|---|---|
| 2026-06-28 | $7.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $28.10M 10-Q · filed 2026-08-07 |
| 2026-03-29 | $20.40M 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |